PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 45
- Registration Number
- NCT00825084
- Locations
- 🇺🇸
Pfizer Investigational Site, Glendale, California, United States
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2009-12-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00824590
- Locations
- 🇺🇸
Pfizer Investigational Site, St. Paul, Minnesota, United States
Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Surgery For Long Bone Fracture
Phase 4
Completed
- Conditions
- Femoral Fractures
- Interventions
- Drug: Tranexamic Acid plus standard of careProcedure: Standard of care
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 82
- Registration Number
- NCT00824564
- Locations
- 🇮🇳
Pfizer Investigational Site, Coimbatore, Tamil Nadu, India
A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1
Phase 2
Terminated
- Conditions
- HIV-1
- Interventions
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 105
- Registration Number
- NCT00823979
- Locations
- 🇧🇷
Hospital Nossa Senhora da Conceicao, PoA, RS, Brazil
🇺🇸Hillsborough County Health Department, Tampa, Florida, United States
🇺🇸Ruth M. Rothstein CORE Center, Chicago, Illinois, United States
A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1
Phase 2
Completed
- Conditions
- HIV-1
- Interventions
- Drug: UK-453, 061Drug: EFV +TVA
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 195
- Registration Number
- NCT00824421
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects
Phase 1
Completed
- Conditions
- HCV
- Interventions
- Drug: [14C]-PF-00868554
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2009-03-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 7
- Registration Number
- NCT00823745
- Locations
- 🇺🇸
Pfizer Investigational Site, Tacoma, Washington, United States
Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2010-07-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3
- Registration Number
- NCT00823966
A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2014-08-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT00824369
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1
Completed
- Conditions
- Multiple MyelomaPlasma Cell Leukemia
- Interventions
- Drug: ARRY-520, KSP(Eg5) inhibitor; intravenousDrug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneousDrug: Dexamethasone, steroid; oral
- First Posted Date
- 2009-01-13
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 55
- Registration Number
- NCT00821249
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Emory University, Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00820742
© Copyright 2025. All Rights Reserved by MedPath